Switzerland
Add to My Companies | Give a Referral for this Company | Print this ProfileCompany details, activities, locations, contacts, financials and reviews for Micreos Pharmaceuticals.
Main company details for Micreos Pharmaceuticals.
Our engineered endolysin technology quickly kills harmful pathogens while preserving the health enhancing microbiome. Endolysins are associated with a low risk of drug resistance development, are highly effective against biofilms and are effective across a broad pH range which is critical important in dermatology. This unlocks a revolutionary approach to treating a wide range of diseases, especially chronic conditions.
Micreos is specialised in dermatology and derm-oncology with our 2 lead development candidates focused on eliminating Staphylococcus aureus (S. aureus) colonisation in patients living with Atopic Dermatitis (AD) and Cutaneous T-cell lymphoma (CTCL).
S. aureus is a common bacteria that is known to cause significant patient morbidity and mortality globally. S. aureus is found on around 20-30% of healthy people, but in chronic conditions like CTCL and Atopic Dermatitis, the rate is as high as 80%. S. aureus worsens clinical outcomes through the release of toxins and super-antigens leading to the proliferation of malignant T-cells in CTCL and more frequent and more severe flare in Atopic Dermatitis.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Micreos Pharmaceuticals on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
